Top 10 money-burning projects in biopharmaceuticals: 5 drugs are on the market and 5 are under study

Pharmaceutical market research institutions recently released a report on the biopharmaceutical field of money-burning projects, involving two categories: drugs in the study (5), listed drugs (5).
following is an introduction to each drug.
in the study of drug 01 Lilly: Tirzepatide Tirzepatide is a weekly glucose-dependent insulin-promoting peptide (GIP, a.g.: gastric suppression polypeptide) and gluatic glucosin-like peptide-1 (GLP-1) peptide double agonist developed by Lilly.
GIP and GLP-1 are both hormones secreted in the intestines that promote insulin secretion.
tirzepatide integrates the effects of two insulin-promoting drugs into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes.
, tirzepatide is also being developed to treat obesity and non-alcoholic fatty hepatitis (NASH).
note that tirzepatide was the first dual GIP/GLP-1 subject exciter to complete Phase 3 trials.
a Phase III SURPASS-1 single-drug treatment study released earlier this month showed that patients in the tirzepatide treatment group had significantly lower blood sugar and weight baselines at 40 weeks of treatment than in the placebo group.
Evaluate Omnium estimates that tirzepatide will spend $617 million on clinical development and $3.1 billion on clinical projects in 2021.
02. Novaral: Pelacarsen (TQJ230) Telacarsen is Novarco's antisanthemum oligonucleotide (ASO) therapy that targets lipoprotein A (ApoA) to reduce the expression of lipoprotein a, thereby reducing the risk of cardiovascular disease.
was first developed by Ionis and its subsidiary, Akcea Therapeutics.
signed an exclusive option agreement with Akcea and Ionis in January 2017 for two drugs under study aimed at reducing cardiovascular risk in patients with high levels of lipoproteina, one of which is TQJ230.
TQJ230 targets the liver with ApoA mRNA, which weakens the expression of liver ApoA, thereby reducing the synthesis and secretion of lipoprotein a and reducing the risk of cardiovascular disease.
clinical study, published in the New England Journal of Medicine in January 2020, showed that pelacarsen therapy led to a dose-dependent reduction in lipoprotein a levels: 20mg once a week, 20mg every 2 weeks, A 4-week 20mg/40mg/60mg reduction in lipoprotein a level was 80 per cent, 58 per cent, 35 per cent/56 per cent/72 per cent lower than the baseline, respectively, compared to 6 per cent for placebo.
Evaluate Omnium estimates that Pelacarsen will spend $283 million on clinical development in 2021 and $1.3 billion on total clinical projects.
03. Sanofi/AZ/SOBI: Nirsevimab Nirsevimab, developed in collaboration with Sanofi, AstraZenecon, and SOBI, is a monoclonal antibody of respiratory syncytial virus (RSV) with an extended half-life (average of 59.3 days) to prevent lower respiratory tract infections (LRTI) caused by RSV.
as a passive immunotherapy, the drug has the potential to provide immunity directly to infants and provide immediate protection against RSV.
current anti-RSV antibody Synagis (palivizumab) is limited to high-risk infants and can only be protected for one month, requiring five injections to cover a typical RSV epidemic season.
Nirsevimab has an extended half-life and is developed for a wider infant population than current standards of care.
Phase IIb clinical trial, published in the New England Journal of Medicine in July, showed that in healthy premature children during the RSV epidemic season, nirsevimab single-dose intramuscular injections significantly reduced the rate of lower respiratory tract infections (RSV-LRTI) caused by RSV and hospitalization compared to placebos.
It is worth noting that this trial is the first to confirm that a single dose of monoclonal antibody (mAb) can significantly reduce RSV-LRTI (including capillary bronchitis and pneumonia) in infants throughout the RSV epidemic season.
Evaluate Omnium estimates that nirsevimab will spend $263 million on clinical development and $1.2 billion on total clinical projects in 2021.
04. Lilly: Mirikizumab Mirikizumab is an humanized IgG4 monoclonal antibody developed by Lilly that targets p19 sub-base in combination with IL-23, and the drug is currently being developed for a variety of immunologic diseases, including plaque psoriasis, ulcerative colitis and Crohn's disease.
In July, Lilly published positive results from the Mirikizumab phase III OASIS-2 study for mirikizumab's treatment of moderate-severe plaque psoriasis, showing that mirikizumab reached the primary and all critical secondary endpoints in week 16 (superiority) compared to placebo.
In addition, mirikizumab reached all critical secondary endpoints in weeks 16 (non-shoddy) and 52 (superior) compared to the Novartis anti-inflammatory drug Cosentyx (IL-17A inhibitor), including the advantages of complete removal of skin damage at week 52.
Evaluate Omnium estimates that mirikizumab will spend $245 million on clinical development in 2021 and $1.4 billion on total clinical projects.
05. Ukip: Bimekizumab Bimekizumab is a unique molecule developed by Yosta that has a dual mechanism of action and can simultaneously and selectively neutralis IL-17A and IL-17F, two key cytokines that drive the inflammatory process.
IL-17A and IL-17F have similar anti-inflammatory functions and work independently with other inflammatory media to drive chronic inflammation and damage in multiple tissues.
currently, bimekizumab is being evaluated for a variety of inflammatory diseases, including plaque-type psoriasis, psoriasis arthritis, strong straight spina blingitis, and non-radiological mid-axis spinal arthritis.
in Phase 3 clinical trials to treat moderate to severe plaque psoriasis, bimekizumab was more effective than AbbVie Humira, Novartis Cosentyx, and Johnson and Johnson Stelara.
September, bimekizumab's application for the treatment of plaque-type psoriasis was accepted by the FDA and the European Union's EMA.
bimekizumab's unique IL-17A/IL-17F dual neutralization may provide a new targeted therapy for the treatment of immunome-mediated inflammatory diseases.
Evaluate Omnium estimates that bimekizumab will spend $227 million on clinical development and $1.3 billion on clinical projects in 2021.
-listed drugs The five most expensive clinical projects in the listed drug category are: Keytruda (Mercado, anti-PD-1 monoantitor), Opdivo (Hundreds of Mespresso, anti-PD-1 single Anti), Tecentriq (Roche/Chinese and foreign pharmaceuticals, anti-PD-L1 monoantigen), Ozempic (No and Nord, GLP-1 agitant), Imfinzi (AstraZenecon, anti-PD-L1 monoantigen).
four of these drugs are anti-PD-1/L1 monoantial, and according to Evaluate Omnium, the total clinical development expenditure for these four drugs in 2021 will be $4,759 million, with a total clinical project expenditure of $40.8 billion.
Ozempic is a weekly, long-acting GLP-1-patient astration for the treatment of type 2 diabetes and for people with type 2 diabetes with cardiovascular disease to reduce the risk of cardiovascular events.
Evaluate Omnium estimates that Ozempic will spend $902 million on clinical development in 2021 and $2.6 billion on total clinical projects.
source: Evaluate Vantage: 2021 Preview